We report a retrospective analysis of 246 myelodysplastic syndrome (MDS) patients in the EBMT (The European Society for Blood and Marrow Transplantation) database who were transplanted for International Prognostic Scoring System (IPSS) low or intermediate-1 disease. The majority of these patients (76%) were reclassified as intermediate or higher risk according to R-IPSS. The 3-year overall survival (OS) and PFS were 58% and 54%, respectively. In a multivariate analysis, adverse risk factors for PFS were marrow blast percentage (hazard ratio (HR): 1.77, P = 0.037), donor/recipient CMV serostatus (donor − /recipient+: HR: 2.02, P = 0.011) and source of stem cells (marrow and non-CR: HR: 5.72, Po 0.0001, marrow and CR: HR: 3.17, P = 0.027). Independent risk factors for OS were disease status at time of transplant and the use of in vivo T-cell depletion (TCD). Patients who did not receive TCD and were transplanted from an unrelated donor had worse OS (HR: 4.08, Po 0.0001). In conclusion, 'lower' risk MDS patients have better outcome than those with 'higher risk' after haematopoietic stem cell transplant (HSCT). Selecting the right source of stem cells, a CMV-positive donor for CMV-positive patients and using in vivo TCD results in the best outcome in these patients. More studies are needed to evaluate the role of HSCT in these patients as compared with conventional treatment.
INTRODUCTION
Allogeneic haematopoietic stem cell transplant (HSCT) is a curative treatment for patients with myelodysplastic syndrome (MDS). HSCT failures are because of immunological complications like GvHD, infections, disease progression and organ dysfunction due to toxicity. Studies designed to demonstrate a benefit of transplant over the best available treatment suggest that there is a gain in life expectancy in patients with International Prognostic Scoring System (IPSS) higher risk (intermediate-2 (int-2) or high) disease as per the IPSS 1 if they receive an allogeneic transplant close to their diagnosis, whereas the lower risk patients (intermediate-1 (int-1) or low) could potentially lose life expectancy if they are transplanted at diagnosis. [2] [3] [4] Recently, a French prospective study confirmed that a better overall survival (OS) is achieved in higher risk patients scheduled for a transplant in comparison with patients who had no donor. 5 Currently, only one-third of these higher risk patients will be alive without progressive disease several years after transplant, with the majority of events (death or relapse) occurring within the first 2 years. [6] [7] [8] For the disparate group of IPSS 'lower risk' MDS patients, transplantation as a treatment option may be offered as a curative treatment in young patients, or because the disease displays poor prognostic factors such as anaemia, thrombocytopenia, increased bone marrow blast count, marrow fibrosis or poor risk cytogenetics. Recently, the presence of somatic mutations in MDS may upgrade the risk of disease progression and may be prognostic. 9, 10 Some low-risk patients have a profile similar to 'higher risk' if mutations in ASXL1, EZH2 or TP53 genes are detected. 11, 12 All of these prognostic features are currently taken into account in making a decision to transplant, although the role of somatic mutations are still under investigation. Usual recommendations concerning transplantation in lower risk patients are to discuss transplant when there is evidence of disease progression on blood or marrow assessment (blasts, cytogenetics, fibrosis) or in young patients with poor cytogenetics. 13 Nevertheless, the 1 transplantation is not urgently needed and is usually performed after several months or years of observation or supportive care. The aim of the present study was to analyse a cohort of patients with low-or int-1-risk MDS who had received a transplant and were registered in the European registry of the EBMT (The European Society for Blood and Marrow Transplantation) in order to report their outcome and to identify potential risk factors for outcome.
MATERIALS AND METHODS

Selection of patients and statistics
Patients who received an HSCT between 2000 and 2011 with a low or intermediate risk at diagnosis as well as at transplant registered in the EBMT registry were included. All centres were asked to participate and only patients with an available classical IPSS 1 in the registry were selected. Cytogenetics were classified according to classical IPSS (poor, intermediate or good). All patients who progressed either because of cytogenetic evolution or increase in blasts 410% (refractory anaemia with excess blasts-2 (RAEB2) or AML) between diagnosis and transplant were excluded (see the flowchart in Supplementary Data. All time-to-event outcomes were calculated from the date of transplant to the date of event or last follow-up. Follow-up was determined according to the reverse Kaplan-Meier method.
14 . Non-relapse mortality (NRM) was considered as death by any cause occurring in patients who did not relapse or progress after HSCT. Death and second transplant were considered as competing event for acute and chronic GvHD. NRM and relapse/progression were considered to be mutually competing risks. OS and PFS functions were estimated using usual methodology. The main analysis relied on Cox proportional hazards models for PFS. Analyses of other outcomes used proportional hazards models for the cause-specific hazard (relapse/progression and NRM) 15 and Cox proportional hazards models (OS).
The following variables were analysed: patient gender, patient age at transplantation, disease classification at time of diagnosis, IPSS, revised IPSS, time from diagnosis to transplant, disease status at transplant (CR or not), transfusion dependence, percentage of marrow blasts at transplant, donor type (HLA-identical sibling or unrelated donor), conditioning regimen (reduced versus myeloablative conditioning regimen, TBI based or not), in vivo T-cell depletion (TCD), GvHD prophylaxis, donor age, source of stem cells (peripheral blood stem cell or bone marrow) and CMV serostatus in recipient and donor.
Multivariable models were built for PFS and OS. Other end points (acute GvHD, chronic GvHD, NRM and relapse/progression) were considered as descriptive, so that cumulative incidence curves were estimated, but no modelling was performed. To build multivariable models, predefined potential prognostic factors were considered, and the final model was selected using a backward stepwise variable selection procedure based on Akaike's information criteria. Once a final model was selected, all two-by-two interactions between selected variables were tested for final model building. The proportional hazards assumption was checked by examination of Schoenfeld residuals and Grambsch and Therneau's lack-of-fit test. 16 Model performance was expressed both in terms of model discrimination, as measured by the concordance probability estimate, 17 and calibration. Missing data were handled through multiple imputations by chained equations methods. 18, 19 As some data were missing (see Table 1 ), 50 independent imputed data sets were generated and analysed separately. 19 Variables used for multiple imputations were not limited. Estimates of model parameters and discrimination indexes were then pooled over the imputations according to Rubin's rule. 18 The model selection was performed on the pooled data set formed by all imputed data sets, with observations Abbreviations: CSA = cyclosporine; IPSS = International Prognostic Scoring System; MMF = mycophenolate mofetil; RA = refractory anemia; RAEB-1 = refractory anaemia with excess blasts-1; RARS = refractory anemia with ringed sideroblast; RCMD = refractory cytopenia with multilineage dysplasia; R-IPSS = revised IPSS. *Four patients had in vitro T-cell depletion.
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weighted by the fraction of non-missing data. 20 The estimation of model performance was estimated within the imputed data sets and then pooled, as recommended. 21 Internal validation was performed using bootstrap resampling with 200 replications. Risk scores derived from the final models were applied to the bootstrap samples and models were refit to derive a correction for overoptimism, both for the model parameters and the concordance probability estimate. 21 All tests were two sided and P-values of ⩽ 0.05 were considered as indicating significant association. Analyses were performed using the R statistical software version 3.0.1 (R Core Team, 2013; http://www.R-project.org.)
RESULTS
Characteristics of the patients and transplantation
A total of 246 patients met the inclusion criteria and could be analysed for this study. All patient characteristics are presented in Table 1 . The median age of recipients was 55 years. The median time from diagnosis to transplant was slightly less than 1 year (11.5 months, range: 1.5 month to 15 years) and 52% of patients were transplanted less than 12 months after diagnosis. In all, 28% of patients had refractory anaemia with excess blasts-1 (RAEB-1), whereas 72% had refractory anaemia or refractory cytopenia with multilineage dysplasia or refractory cytopenia with unilineage dysplasia. In addition, 51 patients were classified as low risk and 195 as int-1 risk according to IPSS. Cytogenetics according to the classical IPSS were good, intermediate and poor in 152 (68%), 61 (27%) and 12 (5%) patients (missing for 21 patients). Cytogenetics as per the revised IPSS were very good in 2 (1%), good in 152 (67%), intermediate in 59 (26%), poor in 13 (6%) and very poor in 13 (6%) patients (missing in 20 patients). When patients were reclassified according to the revised IPSS score, 5% had a very good risk, 18% had a good risk, 55% had an intermediate risk, 20% a poor risk and 1% a very poor risk (missing for 41 patients). Most patients (80%) (57 missing data) received RBC transfusions before the transplant.
Of the patients, 83 (33%) received a line of treatment with the aim of achieving CR before the transplant. Out of these patients, 30 (36%) achieved a CR. At the time of HSCT, 177 (87%) patients had 5 or less than 5% marrow blasts because of the fact that all patients had low or intermediate risk disease. The main source of stem cells was PB (79%) followed by bone marrow (18%) and unrelated cord blood (3%). HLA-matched siblings were donors in 104 (42%) patients. The conditioning regimen was reduced (reduced-intensity conditioning) in 149 (61%) and contained antithymoglobulin (ATG) or alemtuzumab in 151 (61%) patients. More than 90% of patients received cyclosporine-based GvHD prophylaxis combined with methotrexate for half of them (Table 1) .
Outcome and risk factors for outcome With a median follow-up at 41 months, OS, PFS, NRM and relapse rates were 57, 54, 30 and 16% at 3 years ( Figure 1 ). Acute GvHD and chronic GvHD incidences were 30 and 42% at 3 years. Most events occurred within the first 2 years of transplant. The main covariates influencing 3-year OS, PFS, NRM, relapse rate and chronic GvHD probability in the univariate analysis are shown in Table 1 .
Higher blast count was a poor prognostic factor for 3-year OS, as evidenced by the blast counts at transplant (marrow blasts o5%: 60% vs 6-10%: 47%) or based on the FAB disease classification (RAEB: 47% vs other FAB: 73%). There was no obvious effect of patient age, with patients 461 years having a 57% 3-year OS that was similar to that of younger patients, probably because of careful selection of older patients (Table 1) . Patients who were chemotherapy naive had a better 3-year OS than patients who received chemotherapy, irrespective of the response to treatment (untreated: 64%, treated achieving CR: 47%, treated non-CR: 47%). The 3-year OS differed according to the source of stem cells: 68% with cord blood, 52% with PB and 36% with marrow. The 3-year OS was worse in CMV-positive patients receiving a graft from a CMV-negative donor (donor/recipient combination:
− / − 59%, +/ − 54%, − /+45%, +/ − 62%). Cytogenetics according to classical or revised IPSS and global classical or revised IPSS had no major impact on 3-year OS. The 3-year OS was 56 and 59% without or with in vivo TCD, respectively, whereas it was 63 and 54% with ATG and alemtuzumab that was not significantly different.
For multivariate analysis of factors affecting OS, patients receiving cord blood were excluded as the small numbers (n = 8) Figure 1 . OS, PFS and cumulative incidence of NRM. OS, PFS and cumulative incidence of NRM are shown in (a, b and c), respectively. Grey shaded areas represent the 95% pointwise confidence interval.
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precluded confirmation of their effect as an independent factor. The multivariable model confirmed that non-CR patients (hazard ratio (HR): 1.76, P = 0.019) had the highest mortality risk (Table 2 ). There was an interaction between TCD and the type of donor (HLA-matched sibling vs unrelated donor) that had to be taken into account in the Cox model and is shown in Figure 2 . The impact of each combination with TCD/HLA-matched donor as the reference is given in Table 2 . The in vivo TCD in patients transplanted from an HLA-identical donor did not significantly affect the OS. In contrast, patients who received a transplant from an unrelated donor without TCD had a significantly poorer outcome with HR at 4.08 (P o0.001), whereas those receiving TCD had similar outcome to patients who were transplanted from an HLA-identical donor. All other variables were not statistically significant including the age, the date of transplant or the IPSS. Relapse incidence was 16% at 3 years with less relapse in good cytogenetic risk according to IPSS (10% in good risk vs 26% in intermediate risk vs 26% in poor risk) and according to revised IPSS (9% in very good risk vs 12% in good risk 11% in intermediate risk vs 29% in poor risk). The 3-year relapse incidence was higher with marrow use as source of stem cells (marrow: 30%, PB: 12%, cord blood: 14%). The 3-year relapse incidence was not influenced by TCD (17% without TCD, 15% with TCD, 16% for alemtuzumab and 13% for ATG). In the univariate analysis, 3-year PFS probabilities were influenced by similar covariates as those that affected OS, with the exception of the revised IPSS score. Indeed, PFS was lower in patients scored 'poor risk' according to the revised IPSS score (38% vs 60, 48 and 42% for intermediate, good and very good) ( Table 1 ). The very poor category was too small (2 patients) to make any conclusions. Multiple variables analysis for PFS showed that blast count of 45% at the time of transplant (HR: 1.77, P = 0.037), CMV serostatus (negative donor for a positive recipient, HR: 2.02, P = 0.011) and the use of marrow were deleterious for the outcome (Table 3) . As there was an interaction between marrow use and disease status, we detailed results according to both. In untreated patients, the marrow use did not significantly increase the PFS risk (HR: 1.21, P = 0.56) contrary to treated patients in CR (HR: 3.17; P = 0.027) and treated patients not in CR (HR: 5.72; P o 0.0001) who had the highest risk. The lowest PFS risk was seen in untreated patients who received PB (the reference in that model) followed by CR patients who received PB (HR: 1.32) and non-CR patients who received PB (1.54) that were not statistically different from the reference (Figure 2) .
DISCUSSION
This study reports the outcome of low or int-1 MDS patients registered in the European transplant database who represent a minority of the transplanted MDS patients given the fact that transplant indications are usually restricted to the higher risk patients (int-2 and high). 13 The majority of these lower risk patients who received an allogeneic transplant were int-1 (79%) according to classical IPSS. On applying the revised IPSS, it became clear that these patients do not represent a classical cohort of low and int-1 IPSS patients. Indeed, the proportion of higher risk patients according to R-IPSS was higher than expected from the original set of patients published by Greenberg et al. Abbreviations: CI = confidence interval; HR = hazard ratio; TCD = T-cell depletion. Final model after variable selection and correction for overoptimism from imputed data sets. Patients receiving cord blood transplant were excluded from this analysis (n = 8).
transplanted from the low int-1 IPSS group. Thus, this suggested that the population of lower risk patients in this EBMT data set were selected for 'high risk' disease characteristics not included in the original IPSS scoring. Although historically 'low risk' patients have not been reported to benefit from an upfront transplant, it seems that criteria independent from classical IPSS like refractoriness to treatment, young age, marrow fibrosis, poor prognostic somatic mutation, refractory cytopenia or on the basis of their revised IPSS may explain why these patients were allografted although the indication for transplant was not explicitly stated in the database. The data suggest that the outcomes post transplantation were better than usually reported for higher risk patients with 3-year OS and DFS at 58 and 54%, reaching 62 and 59% in patients who had never experienced marrow blast excess, that is, those who were not classified RAEB at any time before transplant. A previous EBMT study, enrolling patients with refractory anaemia transplanted before 2006, has reported a 4-year OS and PFS at 52 and 48%. The cohort was younger (39 years old) than the cohort in the present study (55 years old) and increasing age was identified as a risk factor for increased mortality. The current study confirms that outcomes have probably improved with time as the results presented here, despite an older cohort, are similar to those analysed previously. 23 Although age was not a prognostic factor in univariate or multivariate analyses in this retrospective study, a confounding factor may be that these older patients could have been carefully selected for comorbidity and factors that affect on NRM.
Disease status at transplant was a risk factor for both OS and PFS and was modulated by the source of stem cells for PFS. Untreated patients had a better PFS than treated patients.
Response to treatment influenced the outcome, and patients who did not achieve a CR after treatment had the worst OS, whereas all treated patients regardless of the response to treatment had worse PDS if there had also received marrow as source of stem cell. We hypothesize that either those patients selected to a pre-graft treatment had a more aggressive disease or that pre-graft treatment itself has a deleterious effect on the outcome. As this higher risk in treated patients was not seen in patients who received PB as source of stem cell, characterized by higher rate of chronic GvHD, the first hypothesis is more probable, suggesting that the chemorefractoriness is to some extent ameliorated by the graft-versus-disease effect. Significantly worse PFS was observed in treated patients receiving marrow as source of stem cells. These findings remain consistent with previous studies reporting that PB is the preferred source of stem cells in MDS patients. 24, 25 Of note, the advantage of PB over marrow has usually been restricted to the higher risk patients. In our study, PB stem cells were beneficial in low-risk patients who received a treatment, and this probably represents a higher risk subset of patients among the lower risk as per our aggressive disease hypothesis. The relapse rate using marrow was as high as 30% (vs 12% with PB) that may explain the poorer PFS. In contrast, PB use was associated with higher chronic GvHD incidence (45 vs 31%) that can explain a better control of the disease and graft-versus-MDS effect.
The CMV serostatus combination had a significant effect on PFS. PFS was reduced in CMV-seropositive patients who received a transplant from a seronegative donor. This higher risk of failure (death or relapse) in CMV-positive patients has been reported after myelo-ablative conditioning regimen transplant, 26, 27 but in our study it remained significant even after regimen adjustment.
Finally, the multivariate model revealed that in vivo TCD could not only have a major impact on outcome, but was also related to the type of donor. In patients transplanted from an identical sibling donor, TCD did not affect the OS (or the PFS) but in patients having received a transplant from an unrelated donor, the absence of TCD was particularly deleterious in terms of OS with a HR of 4.08 (P o0.0001). More and more studies including randomized trials 28, 29 have demonstrated the benefit of ATG in myeloid disease but this benefit is usually shown in acute and/or chronic GvHD incidence. To our knowledge, this improved OS with ATG has been scarcely reported but could be specific to low-risk MDS patients. Of note, ATG or alemtuzumab had similar effect.
This study has the drawbacks common to all registry studies that implicate that the results should be taken with caution. Some data were missing or incomplete such as HLA typing that precludes any analysis on the impact of HLA mismatching in patients receiving a graft from an unrelated donor. Because of missing data for some variables, we decided to use multiple imputation for the statistical analysis. As any analytic method, it can be criticized, but is now usually favoured over the strategy of removing patients with missing data. 18 Transfusion dependence could not be studied because of too much missing data (420%). Other studies, specifically raising the question of iron overload impact, are currently ongoing in the Chronic Malignancy Working Party of the European Society for Blood and Marrow Transplant and will be able to evaluate this point in the near future.
To conclude, MDS patients with low and int-1 IPSS score have been transplanted in Europe and their survival appears favourable when compared with higher risk patients. We identified favourable conditions to perform transplantation that can be applied to future candidates with better results when using PB-, ATG-and a CMV-positive donor, especially for CMV-positive recipients. The results of these low-risk patients that have not previously reported as gaining life expectancy with transplantation are of particular importance and have practical consequences. Indeed, more and more patients initially classified as a low-risk MDS patients display poor prognostic features such as somatic mutations and are regularly referred to transplant today. This study gives us the expected outcome of these 'false low-risk patients' even if the registry does not tell us why these patients actually received the transplant. A prospective study testing the role of transplant in lower risk patients with poor prognostic features (poor cytogenetics, somatic mutations, fibrosis, no response to usual treatment and higher score according to the revised IPSS) should be set up to estimate the potential benefit of transplant in these patients. Abbreviations: CI = confidence interval; HR = hazard ratio. Final model after variable selection and correction for overoptimism from imputed data sets.
Patients receiving cord blood transplant were excluded from this analysis (n = 8).
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